Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

72.900
-4.200-5.45%
Volume:949.39K
Turnover:68.76M
Market Cap:41.09B
PE:48.29
High:77.100
Open:77.100
Low:70.600
Close:77.100
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:0.35
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.510
ROE:109.10%
ROA:39.01%
PB:4.22
PE(LYR):48.29
PS:4.39

Loading ...

RemeGen Q1 Profit Of ¥328m Revives Bullish Narratives On Biotech Turnaround

Simply Wall St.
·
Apr 29

RemeGen Swings to Profit in Q1 2026

MT Newswires Live
·
Apr 29

REMEGEN Turns Profitable in Q1 2026 on 24.8% Sales Growth and Sharply Lower R&D Spend

Bulletin Express
·
Apr 28

RemeGen 2025 ESG Report: Energy Intensity Cut by 49%, R&D Investment Reaches RMB1.22 Billion

Bulletin Express
·
Apr 28

荣昌生物2025年实现业绩显著扭转 净利达7.10亿元 营收同比增长89.5%

Bulletin Express
·
Apr 28

HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%

Tiger Newspress
·
Apr 28

Huitianfu Fund Increases Stake in REMEGEN by 79,000 Shares at HK$113.78 Per Share

Stock News
·
Apr 24

Biopharma Stocks Slide Across Board as Oil Prices Squeeze Rate Cut Prospects

Stock News
·
Apr 23

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

Stock Track | REMEGEN Plummets 5.19% Intraday as Profit-Taking Follows Fully Priced-In Catalysts

Stock Track
·
Apr 23

Profitability Reaches 17 Biotech Firms Including BeiGene, Innovent, Beta Pharma, and Remegen

Deep News
·
Apr 21

Why RemeGen (SEHK:9995) Is Up 13.1% After First HER2 ADC–Immunotherapy Approval in China

Simply Wall St.
·
Apr 18

RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results

Bulletin Express
·
Apr 16

CATL Reports 48.52% Surge in Q1 Net Profit to RMB 20.74 Billion

Stock News
·
Apr 16

National Data Administration Proposes Token Trading Exploration; Central Bank Adjusts Overseas Loan Ratios

Stock News
·
Apr 16

Remegen Receives $650 Million Upfront Payment from AbbVie for RC148 Exclusive Licensing Agreement

Stock News
·
Apr 15

Stock Track | REMEGEN Soars 5.17% Intraday on New Drug Approval and Strong Earnings Turnaround

Stock Track
·
Apr 15

BUZZ-RemeGen set for best day in two weeks on China nod for tumour drug application

Reuters
·
Apr 13

RemeGen Drug Approved For Cancer Indication

MT Newswires Live
·
Apr 13

Stock Track | REMEGEN Soars 5.09% Intraday on New Drug Approval and Strong Revenue Growth

Stock Track
·
Apr 13